Iterum reports Q2 net loss $6.5M; ORLYNVAH launch on track for August 2025

Iterum Therapeutics plc

2025-Q2 EPS reported -$0.31

Net loss $6.5M (non-GAAP $5.1M) vs $5.0M prior year; cash $13.0M at June 30, 2025.
ORLYNVAH™ launch expected by end of August 2025 for uUTIs; first oral penem approved in U.S.
Entered commercialization agreement with EVERSANA; hired Christine Coyne as CCO.
Pfizer extended $20M milestone payment deferral to October 2029.
Canadian patent issued covering sulopenem/probenecid combination, expiring 2039.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.